Drugs / CART2219.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05429905 | Jul 2022 → Dec 2024 | adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | KK Women's and Children's Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART 2219.1 | “The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place...” NCT05429905 ↗1“Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia” NCT05429905 ↗ |
| Modality | Cell therapy | “dual-targeting CAR-T cell therapy” NCT05429905 ↗ |
| Route | Intravenous | “intravenous autologous anti-CD22/CD19 CAR-T” NCT05429905 ↗ |
| Target | CD19 | “Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells” NCT05429905 ↗ |
| Target | CD22 | “Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells” NCT05429905 ↗ |